In comparison with major diseases, the targeting of rare diseases poses many different challenges, necessitating consideration of bespoke R&D strategies for successful drug discovery efforts to be successful. This report examines the issue that need to be considered in the earliest stages of embarking on a rare disease project.
Features and benefits
Highlights
While disease prevalence has an impact on the commercial viability of a new treatment, returns are achievable even for ultra rare conditions. Rare diseases can provide sufficient opportunities for commercialization of multiple therapeutic agents. This is the case even for some ultra rare conditions such as Gaucher disease and Fabry disease.
Both clinical experts and patient groups provide valuable resources in understanding a rare disease and in identifying potential patients for clinical studies.
Many opportunities remain to develop treatments for untreated rare diseases. However, ultra rare diseases with high infant mortality present major challenges.
Your key questions answered